Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2011

Apr 21, 2011

33651_dirs_2011-04-21_b10c54b9-1828-4c73-b519-a338ddb01ad8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-04-13

Reporting Person: Kennedy Robert Eugene (Vice President and CFO)